1. Scrip
  2. >>Leadership

Profile: VC Forbion's Slootweg Sees Bigger And Better European Funds

 
• By Lubna Ahmed

Sander Slootweg, managing partner and co-founder of Forbion Capital Partners, talks venture capital trends, industrial changes to watch, deal making and challenges faced during his years investing in the life science industry in the latest instalment of Scrip's executive profile series.

SANDER SLOOTWEG
Sander Slootweg, Forbion Capital Partners

Before co-founding Forbion Capital Partners as a spin-out of ABN AMRO Capital Life Sciences in 2006, Slootweg was an investment director at ABN AMRO Capital Life Sciences. As Forbion's managing partner, Slootweg played a big role in selling BioVex Inc. to Amgen Inc. in 2011 for up to $1bn and the sale of Dezima Pharma BV, also to Amgen, in 2015 for around $1.55bn. He is currently on the board of Forbion portfolio companies Xention Discovery Ltd, Pulmagen Therapeutics Ltd, Oxyrane Ltd and Replimune Ltd.

Slootweg discussed with Scrip his experience in the venture capital business, and his thoughts about the direction of biotechnology investment.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 
• By Eleanor Malone, Edwin Elmhirst, and Kosh Naran

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

In Brief: Gilead HIV Trials On Hold Over Safety Signal

 
• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.